GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.

@article{Liu2015GLP1RA,
  title={GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.},
  author={Jia Liu and Guang Lu Wang and Yumei Jia and Yuan Xu},
  journal={Diabetes/metabolism research and reviews},
  year={2015},
  volume={31 4},
  pages={329-35}
}
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases, and its incidence has been increasing recently. In addition to hepatic complications, NAFLD is also recognized as an independent risk factor for cardiovascular disease. Unfortunately, the current therapies for NAFLD display variable efficacy; a novel and effective drug is urgently needed. Glucagon-like peptide-1 (GLP-1), a receptor agonist is a new drug approved for treating type 2 diabetes. Recently, these… CONTINUE READING